Abstract
By measuring quantitatively the active efflux of cephalosporins by an RND (resistance-nodulation-division) family efflux pump AcrB in intact cells of Escherichia coli, we found that the simultaneous presence of another substrate, such as chloramphenicol, benzene, cyclohexane, or Arg β-naphthilamide significantly enhanced the extrusion of cephalosporins. The stimulation occurred also in a strain expressing the covalently linked trimer of AcrB, and thus cannot be ascribed to the enhanced assembly of the trimer from AcrB monomers. When Val139 of AcrB was changed into Phe, the stimulation by benzene was found to occur at much lower concentration of the solvent. A plausible explanation of these observations is that the AcrB pump is constructed to pump out very rapidly the solvent or chloramphenicol molecules, and thus the efflux of cephalosporins, which presumably bind to a different subsite within the large binding pocket of AcrB, can become facilitated. Computer simulations of ligand binding to AcrB, both by docking and by molecular dynamics simulations, produced results supporting and extending this hypothesis. Benzene and the cephalosporin nitrocefin can bind simultaneously to the distal binding pocket of AcrB, both in the wild type and in the V139F variant. Interestingly, while the binding position and strength of benzene are almost unaffected by the presence of nitrocefin, this latter substrate is significantly displaced towards the exit gate in both wild type and mutant transporter in the presence of benzene. Additionally, the cephalosporin efflux may be enhanced by the binding of solvents (sometimes to the cephalosporin-free protomer) which could accelerate AcrB conformational changes necessary for substrate extrusion.
Keywords: multidrug efflux, solvents, cephalosporins, chloramphenicol, positive cooperativity
Introduction
RND (Resistance-Nodulation-Division) family transporters1, such as AcrB of Escherichia coli, pump out drug molecules mostly from the periplasm of Gram-negative bacteria directly into the external medium, through collaboration with an outer membrane channel (TolC in the case of AcrB) and a periplasmic accessory protein (AcrA in the case of AcrB)2. Some of these transporters, including AcrB, handle a very wide range of ligands, including antibiotics, biocides, dyes, detergents3, and even simple solvents4, 5. In our previous attempt to predict the binding of these ligands to the deep binding pocket of the AcrB protein6, we used computer prediction algorithm of Autodock Vina and found that some ligands, including nitrocefin, bind to the narrow “groove” of the pocket whereas others, including chloramphenicol and benzene, bound to a much wider “cave” area of this large pocket. We examined whether the simultaneous presence of two ligands results in competition. As we can measure the efflux of nitrocefin in a quantitative, real-time assay7, this was followed in the presence of minocycline, a groove-binder, and of chloramphenicol, a cave-binder. The results showed that minocycline strongly inhibited the efflux of nitrocefin presumably by interfering with the binding of the latter to the groove, whereas there was no evidence of inhibition when chloramphenicol was added6.
Examination of chloramphenicol data suggested in addition that the drug, especially at higher concentrations, actually may enhance, rather than inhibit, the efflux of nitrocefin. Because such mutual stimulation between ligands, if true, may shed light into the mechanism of efflux transport, we began by confirming the reproducibility of these data. We then found that other ligands, especially solvents such as benzene and cyclohexane, which are substrates of the AcrB pump4, 5, strongly accelerated the efflux of nitrocefin and another cephalosporin, cefamandole. We examined the binding of both nitrocefin and benzene to AcrB both by computer docking and by molecular dynamics simulation, and discuss possible mechanisms of this stimulation phenomenon.
EXPERIMENTAL PROCEDURES
Bacterial strains
For the measurement of cephalosporin efflux, E. coli K12 strains HN1157 and HN11607 were used for nitrocefin and cefamandole, respectively. In both of these strains, the expression of the AcrAB efflux pump was increased by the deletion of the acrR repressor gene. HN1157 also contained a mutated porin gene producing a larger pore channel, so that the influx of nitrocefin across the outer membrane was facilitated. In HN1160, the endogenous AmpC β-lactamase, with low KM values for cephalosporins, was replaced by the TEM β-lactamase with much higher KM values.
Culture of strains and nitrocefin efflux assay in the presence and absence of other substrates
Strains were grown in M63 medium ((NH4)2SO4 15 mM; MgSO4 1 mM; FeSO4 1.3 µM; 0.1 M K-phosphate buffer at pH 7.0; 0.2% glucose) at 30C with shaking until the cell culture reached an OD600 of 0.65. For the growth of HN1160, arginine (20 µg/ml) and thiamine (1 µg/ml) were added to this medium. Cells were harvested by centrifugation, washed twice and re-suspended in 50mM potassium phosphate buffer, pH 7.0 containing 5mM MgCl2 to a final OD600 of 0.8. Samples were split into two sets of cuvettes. In one set, a stimulator substrate was added to a specified final concentration. In the other set, no substrate was added. Samples were pre-incubated at room temperature for 5 to 10 min. Nitrocefin or cefamandole was then added, and efflux assays were performed as described previously7.
Construction of an acrB mutant and gene replacement in E. coli genome
First, the wild type sequence of acrB from HN11577 was amplified by PCR and cloned into pSPORT1 vector between BamHI and SmaI restriction sites. The mutation V139F was introduced by site-directed mutagenesis using pfu Ultra High fidelity DNA polymerase (Agilent) as described by the manufacturer. The mutant gene was then subcloned into pKO3 vector8 between BamHI and SmaI restriction sites, giving pKO3/acrB_V139F plasmid. This plasmid was electroporated into HN1157, the chromosomal integrates were selected at 42C, and the strains that lost the vector sequence was selected with 5% sucrose8, resulting in the strains in which the acrB gene was replaced with the mutant gene coding for the V139F sequence. Gene replacement was confirmed by PCR using a forward primer annealing on acrA and a reverse primer annealing on acrB, followed by DNA sequencing. The oligonucleotide primers used for PCR amplification and site-directed mutagenesis are shown in Table1 of the Supporting Material.
Table 1.
KM and Vmax of nitrocefin efflux.
Strains used |
Without additive | With Additive | |||
---|---|---|---|---|---|
KM | Vmax | Additive | KM | Vmax | |
Wild type | 10.3 ± 1.9 (9) | 36.1 ± 9.8 (9) | 0.1 mM Benzene | 6.4 ± 0.1 (3) | 41 ± 12 (3) |
0.1 mM Cyclohexane | 7.0; 9.6 | 36; 26 | |||
0.1 mM Cyclohexanone | 10.4 ± 2.6 (4) | 47 ± 5 (4) | |||
V139F | 10.2 ± 2.8 (10) | 43.7 ± 14.6 (10) | 0.1 mM Benzene | 4.1 ± 1.8 (3) | 46 ± 15 (3) |
0.1 mM Cyclohexane | 6.7 ± 2.6 (5) | 48 ± 12 (5) | |||
0.1 mM Cyclohexanone | 5.1; 16.4 | 49; 72 |
KM and Vmax values shown are average ± S.D., except in those cases where only two experiments were carried out, and in units of µM and pmol/s/mg (dry weight) cells, respectively. The numbers in parentheses show the number of independent experiments.
Determination of minimal inhibitory concentration (MIC)
MIC of nitrocefin was determined in the presence and absence of 32 µg/ml Arg β-naphthylamine, by streaking a culture of HN1157 on an LB plate containing a linear gradient of nitrocefin (0 to 25 µg/ml) and by incubating the plate overnight at 37 °C.
Docking and MD simulations
Docking
In the bi-molecular complexes the starting position of each substrate within the distal pocket of the Binding protomer (for MD simulation) was taken either from our previous study9 or from docking calculations performed with the AUTODOCK VINA package10 using as a target the crystal structure of AcrB11 (wt protein) and that resulting from structural relaxation of mutant AcrB free of substrates (V139F variant). The latter model was constructed by introducing the V139F mutation in the Binding Protomer of the AcrB model 2J8S11 through the mutator plugin of VMD12, following the procedure described earlier13. After preliminary energy minimization by this program, the structure was optimized by MD simulation.
In the tri-molecular complexes, the second ligand was docked on the two top conformations extracted from the MD simulation of bi-molecular complexes, by a cluster analysis performed on the equilibrium trajectories. Further details are described in Supporting Information.
MD simulations
The setup for the MD simulations of bi- and tri-molecular complexes was identical to that reported previously9. A reduced model of the protein was used, only including the periplasmic loops responsible for the substrate specificity of AcrB14. Further details and calculation of binding energy through MM/GBSA approach and metadynamics are described in Supporting Information.
RESULTS
Nitrocefin efflux is stimulated by chloramphenicol
In our previous study comparing the effects of minocycline and chloramphenicol on the efflux of nitrocefin6, we noted that the former acted as a powerful inhibitor whereas the latter showed no visible inhibition. A careful examination of these data showed that there was a slight stimulation of nitrocefin efflux in the presence of chloramphenicol, however at that time only efflux rates at different external concentrations of nitrocefin were compared. To confirm that the stimulation was real, a more thorough analysis was performed in which we examined the precise kinetics of efflux, by plotting the efflux rates at different nitrocefin concentrations in the periplasm, where its capture takes place7. Such an analysis (Fig. 1) showed that the stimulation was slight but real, mainly resulting from approximately 20% increase in Vmax and possibly also from a decrease in KM (less than 10%).
Figure 1.
Chloramphenicol stimulates the efflux of nitrocefin. The efflux rate (Ve) of nitrocefin is plotted against its periplasmic concentration (Cp). Measurement was carried out in the absence (○) and presence (■) of 0.1 mM chloramphenicol. This experiment was repeated and gave essentially identical results.
Nitrocefin efflux is stimulated by solvents
We tried to find other AcrB substrates that stimulated the efflux of nitrocefin more strongly, so that further analysis would become facilitated. High concentrations (30 mM) of both benzene and cyclohexane produced strong stimulation of nitrocefin efflux (Fig. 2A and 2B). Similarly, 25 mM cyclohexanone produced a remarkable activation of nitrocefin flux (Fig. 2C). We examined the possibility that the solvents might be directly interfering with the hydrolysis of nitrocefin catalyzed by the AmpC β-lactamase. However, the solvents had no effect on nitrocefin hydrolysis by the sonicated cell extracts. At these high concentrations, solvents caused increases in the Vmax values, and often decreased the values of KM; for example, in two experiments with benzene, Vmax was increased about twofold, and KM was decreased also twofold (not shown).
Figure 2.
Stimulation of nitrocefin efflux by high concentrations (30 mM) of benzene (A) and cyclohexane (B), and 25 mM of cyclohexanone (C). Benzene and cyclohexane were added as a 1:1 (vol:vol) mixture with ethanol, and the same volume of 50% aqueous ethanol was added to the control. Cyclohexanone was similarly added as a 1:1 mixture with dimethylsulfoxide. As in Fig. 1, the efflux rates of nitrocefin (Ve) are plotted against its periplasmic concentrations (Cp). Measurement was carried out in the absence (○) and presence (■) of solvents. These experiments were repeated several times for each solvent, and reproducible results were obtained.
Although these results were encouraging, solvents were used at concentrations much higher than that of the measured efflux substrate, nitrocefin. At such concentrations we cannot exclude the possibility that solvent effect was caused by their strong partition into the bilayer, which may affect the function of the transporter. (However, this mechanism is unlikely in the V139F mutant AcrB described below). At concentrations comparable to the nitrocefin concentration, i.e. around 0.1 mM, the effect was more modest, although a clear indication of stimulation was seen (see below). We have tested a number of other potential substrates of the AcrB pump at 0.1 mM concentration. We could not find any evidence of stimulation of nitrocefin efflux in the presence of the following substrates: deoxycholate, taurocholate, novobiocin, erythromycin, azithromycin, ciprofloxacin, norfloxacin, and nalidixic acid (results not shown).
Nitrocefin efflux is stimulated by Arg β-naphthylamide
The well-known AcrB inhibitor (and substrate15) Phe-Arg β-naphthylamide inhibited nitrocefin efflux when used at a low concentration (20 µM), but at a higher concentration (0.1 mM) it often produced stimulation (results not shown). Although this compound was recently reported to increase the non-specific permeability of the outer membrane16, 17, such an effect at high concentrations was known already at the time of its discovery15 and its activity as an efflux inhibitor is supported by a large number of studies18. Because Phe-Arg β-naphthylamide is hydrolyzed by intact E. coli cells first into Phe and Arg β-naphthylamide by peptidase N (T. May and H. Nikaido, unpublished), Arg β-naphthylamide was tested and indeed found to be a powerful stimulant of nitrocefin efflux (Fig. 3). A large decrease in the values of KM (81 ± 6.3 % decrease in four experiments) played a major part here, although there was also a modest increase in Vmax in all experiments. Neither Phe nor the further hydrolysis product of Arg β-naphthylamide, Arg and β-naphthylamine, produced significant stimulation (or inhibition).
Figure 3.
Stimulation of nitrocefin efflux by 0.1 mM Arg-β-naphthylamide. As in Fig. 1, Ve of nitrocefin is plotted against its Cp. Measurement was carried out in the absence (○) and presence (■) of Arg-β-naphthylamide. This experiment was repeated several times and reproducible data were obtained (see text).
When nitrocefin MIC was determined by using the gradient plate method in the presence of 32 µg/ml (0.107 mM) Arg β-naphthylamide, there was a slight but reproducible increase in MIC, from 11.1 to 13.1 µg/ml, consistent with the stimulation of nitrocefin efflux (Fig. S1). Although the increase was smaller than expected, this could be due to the instability of the stimulator, Arg β-naphthylamide, which is hydrolyzed by peptidase N.
Efflux of cefamandole is also stimulated by solvents and chloramphenicol
Nitrocefin binds very tightly to the distal binding pocket of AcrB9, and its transport KM is by far the lowest among the cephalosporins tested7. In order to show that the stimulation phenomenon is not solely limited to this tight-binding substrate, we used cefamandole, which is expected to bind less tightly than nitrocefin to the binding site, with the calculated binding energy (in docking with Autodock Vina) of −9.2 kcal/mol in contrast to that of −10.2 kcal/mol for nitrocefin. Indeed, cefamandole is pumped out by AcrB with a much higher K0.5 value of around 20 µM than the KM of nitrocefin (around 5 µM)7. Cefamandole efflux was indeed stimulated by 0.1 mM and 30 mM benzene (Fig. 4A and B) reproducibly. Chloramphenicol (0.1 mM) also produced a significant stimulation of cefamandole efflux (Fig. 4C). The efflux kinetics of cefamandole shows a strong cooperativity7, and thus its analysis becomes more complicated. However, the stimulation again seems to be caused mainly by increases in Vmax and decreases in K0.5. Interestingly, in all experiments there appeared to be a significant decrease in apparent cooperativity, the calculated Hill coefficients decreasing to 63, 81, 81, and 91% of the no-solvent control value (average 2.69) in the four experiments with 30 mM benzene.
Figure 4.
Stimulation of cefamandole efflux by 30 mM (A) and 0.1 mM (B) benzene, as well as 0.1 mM chloramphenicol (C). Measurement was carried out in the absence (■) and presence (◆) of stimulants. Each of these experiments was repeated several times, and reproducible results were obtained.
Stimulation of nitrocefin efflux is not caused by the accelerated assembly of AcrB trimer
According to the functionally rotating trimer concept of AcrB function, AcrB cannot perform its efflux function unless it is assembled into a homotrimer. Thus it is possible that solvents stimulate the efflux by somehow facilitating the assembly of the AcrB trimer. This was tested by using the covalently linked, giant AcrB trimer produced from the modified gene coding for such a complex19. The stimulatory effect of benzene was indeed confirmed in the linked trimer (Fig. 5)
Figure 5.
Stimulation of nitrocefin efflux occurs also in a covalently linked AcrB trimer. This figure shows a representative experiment in which nitrocefin efflux was measured in the absence (○) and presence (■) of 30 mM benzene.
Studies with the V139F mutant AcrB
The results presented above suggested that the effect of stimulants (such as solvents) is likely to involve the interaction (either direct or allosteric) of these ligands and cephalosporins in an AcrB trimer. In an effort to understand how this interaction could occur within the large (distal) binding pocket of AcrB, docking prediction was made with Autodock Vina. The calculated binding energy of benzene to the AcrB binding pocket was quite small (−5.1 kcal/mol), and it appeared to bind to the lower (i.e. closer to the membrane surface) part of the binding pocket, earlier called “cave”6, at a location closest to the Val139 residue (with the closest distance of 3.2 Å) (Fig. 6). We thus tried to strengthen the binding of benzene to this region of the binding pocket by mutating Val139 to a Phe residue. This mutation was constructed and the wild-type acrB gene was replaced by this mutant gene as described in Experimental Procedures.
Figure 6.
Docked position of benzene in the Binding Protomer of AcrB. This picture was produced by using the program PyMol.
When nitrocefin efflux was measured in this mutant, a much stronger stimulation by 0.1 mM benzene was observed (Fig. 7B), in comparison with the cells producing the wild type AcrB (Fig. 7A). In the mutant, stimulation was apparently caused by an increase (about 60%) in Vmax, and a strong decrease (by about 60%) in KM. It was stimulated less strongly by the presence of 0.1 mM cyclohexane, however (Table 1).
Figure 7.
Stimulation of nitrocefin efflux by a low concentration (0.1 mM) of benzene. A. Cells producing the wild type AcrB. B. Cells producing the V139F mutant AcrB. These experiments were repeated several times, and similar results were obtained (see Table 1).
Docking studies
In an effort to understand the mechanism of stimulation of nitrocefin and cephamandole efflux by various ligands, we examined the binding of the substrates and stimulators to the distal binding pocket of the binding protomer of AcrB with Autodock Vina. Initially, we focused on benzene and nitrocefin, which were predicted to bind to two distinct sub-areas of the binding pocket. Benzene was predicted to bind to the lower part of the pocket, previously named “cave”6, with a low affinity (−5.1 kcal). Nitrocefin, which is predicted to bind very tightly to the pocket of the free AcrB (with the calculated energy of −10.2 kcal), was found to bind less tightly to AcrB with a pre-bound benzene (−9.4 kcal) as the thiophene ring of nitrocefin clashes with the benzene, and was thus displaced by this molecule. As for cefamandole, it is predicted to bind somewhat less tightly (−9.2 kcal) than nitrocefin, exclusively to the upper, “groove” region of the pocket6, and thus will be less affected by the binding of benzene to the lower region of the pocket. However, Autodock Vina predicts that Arg β-naphthylamide binds tightly (−9.9 kcal) to the subdomain that is also occupied by nitrocefin, and the effort to dock nitrocefin to AcrB with the pre-bound Arg β-naphthylamide ended up with the prediction that nitrocefin will preferentially bind to sites that are completely outside of the pocket.
Similar docking studies were carried out with an MD-simulation-optimized model of V139F mutant AcrB. Compared with the wild-type AcrB, benzene was indeed found to bind with a higher affinity (−8.5 kcal), and nitrocefin with a lower affinity (−8.6 kcal).
MD simulation studies
Because docking cannot take into account the effect of water molecules and the substrate-induced changes in the conformation of the binding site, we examined some of these interactions by MD simulations, concentrating on nitrocefin and benzene (Table S1).
(i) Benzene alone
We started from the most stable docked structures of the benzene-(wild type)AcrB complex (Fig. 8A). In one simulation, benzene kept hopping between two different positions in the binding site (Fig. 8B–C and Figs. S2 and S3). Calculated binding free energies were similar at these two positions (Table 2). In another simulation, starting from a different but energy-equivalent binding pose, benzene remained essentially in the same, lower part of the binding pocket (Figs. 8D). In all the poses, benzene tended to be loosely surrounded by several hydrophobic residues, including the aromatic F136, F178, Y327, V571, F610, and F628 (Table S2).
Figure 8.
Binding of benzene to the distal pocket of wt (A–D) and V139F variant (E–G) of AcrB. Sidechains of residues belonging to regions defined earlier9 and within 3.5 A from benzene are shown with solid sticks, with the following color code: distal pocket: red; cleft: orange; proximal pocket: green; distal/proximal pocket interface: blue; G-loop: yellow. V/F139 are shown with thicker sticks. Benzene is shown with cyan sticks, and the G-loop is highlighted in yellow for each pose. Docking conformations of benzene and of the G-loop are shown in grey in B–D and F–G. Residues not belonging to any relevant region are shown with transparent sticks.
A. Docking position in wt AcrB; B, C. Representative conformations, BNZWT (11) and BNZWT (12), sampled in simulation BNZWT (1); D Representative conformation from BNZWT (2); E. Docking position of BNZ in V139F AcrB; F–G. Representative conformations sampled in simulations BNZV139F (1) and BNZV139F (2).
Table 2.
Free energies and surface matching coefficients
Compounda | ΔGbb | Matching and Interactions | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
ΔGsolv | % of ΔGb | Surface Matching | Structure | ||||||||
Dist. Pcktc | Prox. Pckt | G-loop | Interface | Ext. Cleft | BNZ/NCF | SMTotd | SMLd | HB | Stack | ||
BNZWT (11) | −11.6±1.3 | −3.3 (28/59) | - | - | −0.4 (3/8) | - | - | 1.00 | 1.00 | - | 1.07 |
BNZWT (12) | −11.0±1.3 | −1.8 (28/59) | −0.2 (1/3) | −0.2 (2/5) | −0.4 (3/9) | −0.7 (6/17) | - | 0.96 | 0.98 | - | - |
BNZWT (2) | −11.9±1.3 | −3.3 (27/58) | - | - | - | −0.3 (2/6) | - | 1.00 | 1.00 | - | 0.76 |
BNZV139F (1) | −12.3±1.5 | −3.4 (27/56) | - | - | - | - | - | 1.00 | 1.00 | - | 1.46 |
BNZV139F (2) | −12.5±1.2 | −3.2 (24/55) | - | - | - | - | - | 0.87 | 0.93 | - | 0.57 |
NCFWT | −38.9±3.8 | −17.4 (44/68) | −1.2 (3/4) | - | −1.0 (2/3) | - | - | 0.62 | 0.78 | - | 0.61 |
NCFV139F | −42.0±3.8 | −14.1 (33/54) | - | - | - | - | - | 0.49 | 0.63 | - | 0.87 |
NCF-BNZWT (1, NCF) | −34.2±3.7 | −11.2 (32/53) | - | −2.8 (8/13) | - | - | −0.6 (2) | n.c. | n.c. | n.c. | n.c. |
NCF-BNZWT (1, BNZ) | −12.2±1.5 | −2.6 (21/45) | - | −0.3 (2/5) | −0.3 (2/5) | - | −0.4 (3) | n.c. | n.c. | n.c. | n.c. |
NCF-BNZWT (2, NCF) | −32.9±4.4 | −15.7 (47/65) | - | - | - | - | - | n.c. | n.c. | n.c. | n.c. |
NCF-BNZWT (2, BNZ) | −13.0±1.6 | −2.3 (18/48) | - | −0.5 (3/9) | −0.4 (3/8) | −0.4 (3/8) | - | n.c. | n.c. | n.c. | n.c. |
NCF-BNZV139F (1, NCF) | −41.2±3.4 | −18.2 (44/58) | - | −2.3 (5/7) | - | - | - | n.c. | n.c. | n.c. | n.c. |
NCF-BNZV139F (1, BNZ) | −11.1±1.8 | −3.2 (28/60) | - | - | −0.5 (4/9) | - | - | n.c. | n.c. | n.c. | n.c. |
NCF-BNZV139F (2, NCF) | −41.1±2.8 | −18.0 (42/64) | - | - | - | - | - | n.c. | n.c. | n.c. | n.c. |
NCF-BNZV139F (2, BNZ) | −12.4±1.2 | −3.3 (26/56) | - | - | −0.2 (1/3) | - | - | n.c. | n.c. | n.c. | n.c. |
Numbers 1 and 2 in parenthesis refer to the simulation number thereon, with BNZWT (11) and BNZWT (12) indicating the two clusters of conformations found in the simulation of BNZWT (1). The numbers in parentheses after the values of the contributions to ΔGsolv from different regions indicate the percentages over the total free energy of binding (before slash) and the fraction of the total residues’ contribution (after slash). n.c.: not calculated.
The calculations for all compounds refer to the drugs bound to the distal pocket of the Binding protomer.
The contribution of the configurational entropy of the solute has not been included (see SI). Concerning the contributions of different regions to ΔGb, only those larger than 2% are listed.
In the V139F AcrB, the initial docked position showed benzene indeed interacting more tightly (see above) with the phenyl group of the newly created F139 with a loose stacking interaction at the distance of about 4 Å (Fig. 8E). At the end of MD simulations, the binding site has undergone significant changes of conformation, and in two independent MD simulations the benzene molecule became sandwiched between the F139 and F628 (Figs. 8F–G), although its binding position did not change dramatically with respect to that in wild type AcrB (Fig. S3). Also the key residues stabilizing benzene within the pocket were well-conserved compared to the complex with the unaltered AcrB (Table S2).
In the MD simulations, benzene seemed to bind more stably to the V139F variant of AcrB (Fig S3A), yet the MM/GBSA approach was unable to reflect this feature in the values of the binding free energy (see Table 2), possibly because the entropy term was not included9. We therefore used a more powerful approach, metadynamics20–23(see Experimental Procedure in Supporting Information) in order to evaluate the free energy cost associated with the displacement of benzene from the Phe-rich cage. This quantity can be related to the residence time of benzene in the binding pocket, which in turn might be inversely related to the rate at which AcrB conformational changes occur along the functional rotation cycles (see Discussion). We chose a simple and intuitive collective variable (CV) to be biased, i.e. the distance between the centers of mass of benzene and of residues surrounding it (see Supporting Information). The affinity of benzene was indeed higher for the mutated than for the wild type protein. Namely, the packing of the solvent by residues F136 and F139 increases by ~3 kcal/mol the free energy barrier associated to unbinding from the most stable position in the pocket (Fig. S4). In addition to the well-tempered metadynamics simulations, we performed an additional set of standard metadynamics simulations, without any wall on the distance between benzene and the center of mass of the pocket. Interestingly, in three different simulations performed for each system, benzene exited the protein from the external cleft in the wild type complex, and reached the exit gate in the mutated protein (data not shown). This surprising finding, however, is consistent with a larger stimulation, by benzene, of nitrocefin efflux in the V139F variant (Fig. 7B).
(ii) Nitrocefin alone
We extended to 165 ns the simulation of the nitrocefin-(wild type)AcrB reported earlier9 (Table S1), but there were no significant changes in the binding position and affinity (Figs. 9A–B and Table 2). When docking of nitrocefin was carried out with AcrBV139F, the binding was weaker than with the wild type AcrB, as described above. One of the few prominent interaction was the loose (~4 Å) sandwiching of the thiophene ring of nitrocefin between F139 and F628 (Fig. 9C). In the subsequent MD simulation nitrocefin contacts with the protein and water were optimized, and the thiophene ring lost contacts with F139 (Fig. 9D).
Figure 9.
Binding of nitrocefin to the distal pocket of wt (A–B) and V139F variant (C–D) of AcrB. A. Docking position in wt AcrB; B. Representative conformations sampled in NCFWT; C. Docking position in the V139F AcrB; D. Representative conformations sampled in NCFV139F (1).
(iii) Nitrocefin binding to benzene-AcrB complex
We investigated how nitrocefin binding is affected by the presence of a benzene molecule in AcrB. When docking of nitrocefin was carried out using representative benzene-AcrB(wild type) conformations optimized by MD simulations, we found that it bound less tightly to the transporter: the binding energy calculated by Vina (obtained by empirical methods, and cannot be compared to the free energies in Table 2) were in the range of −8.0 to −9.1 kcal/mol, weaker than the −10.2 kcal/mol energy obtained for wild type AcrB free of benzene. Two opposite orientations of nitrocefin were found to be compatible with pre-bound benzene in the distal pocket (data not shown). The difference in affinity compared to the bimolecular complex was retained in the binding free energy calculated over the two MD trajectories (one per orientation of nitrocefin) of the trimolecular system nitrocefin-benzene-AcrB (Table 2).
Interestingly, compared with the bimolecular complexes, in one of the MD simulations benzene moved by a few Å towards the upper part of the distal pocket (Fig 10A), and the pattern of stabilizing contacts was only partly conserved (Table S2). In both wild type and mutant tri-molecular complexes, nitrocefin moved more significantly in the direction of the Exit Gate towards the TolC docking domain11, with the carboxyl group facing residues Q124 and Y758 (compare the stick models of nitrocefin in green and lime with those in red and mauve in Fig. 10B). This movement of the substrate was also seen in the second MD simulation started from a different conformation of the benzene-AcrB complex (where nitrocefin assumed a flipped orientation with respect to the first simulation, see Figs. S5A and S5C), although its magnitude was somewhat less (Table S1). In this case the axis of nitrocefin was not fully aligned to the Binding Pocket-Gate direction. Several key interactions with residues of the binding pocket were retained despite this displacement (Table S3), although the overall interaction strength was reduced (Table 2). MD simulations thus showed that the two substrates can bind simultaneously to the distal pocket, benzene in the bottom and nitrocefin (in two opposite orientations) in the upper part, closer to the Exit Gate.
Figure 10.
Binding positions of benzene (A) and nitrocefin (B) in the bi- and tri-molecular complexes with AcrB. Thinner and thicker sticks represents the ligands in the bi-molecular and tri-molecular adducts respectively. Red and magenta indicate the wt complexes, while green and lime indicate the mutated ones. The protein is shown in cartoons and is colored according to the secondary structure. Residues Q124 and Y758 lining the gate to the central funnel are shown with ice blue beads.
DISCUSSION
We detected some hints earlier6 that the presence of one ligand, chloramphenicol, may enhance the efflux of another ligand, nitrocefin, added at the same time. The differences were small, yet this conclusion could be confirmed in the present study (Fig. 1). We further showed in this study that, when tested at high concentrations (around 30 mM), simple solvents such as benzene, cyclohexane, and cyclohexanone stimulated much more strongly the efflux of nitrocefin, partly by increasing its Vmax for transport (Fig. 2). Other than the solvents, Arg β-naphthylamide stimulated nitrocefin efflux strongly (Fig. 3). In a mutant AcrB (V139F), benzene could produce a strong stimulation of nitrocefin efflux even at a low concentration of 0.1 mM (Fig. 7B). Finally, benzene and chloramphenicol produced a modest but reproducible stimulation of the efflux of cefamandole (Fig. 4), another cephalosporin.
Stimulation, by one substrate, of the efflux of another substrate is not unknown in the behavior of multidrug transporters. It is well-known that the transport of Hoechst 33342 dye by the P-glycoprotein is stimulated by the simultaneous presence of another substrate, rhodamine 12324, 25, an observation that led to the assumption that there are two distinct substrate binding sites (H-site and R-site for the Hoechst dye and rhodamine, respectively) that are separated by a measurable distance26. Since P-glycoprotein functions as a monomer, such stimulation phenomena likely involve allosteric conformational changes introduced by the binding of one of the substrates27. In contrast, AcrB operates as a trimer, and the binding and export of substrates presumably involves tight interaction between the neighboring protomers11,28,29; thus the mechanism of stimulation may be more complex.
One trivial mechanism involves the accelerated assembly of AcrB trimer by the stimulator substrate, but we were able to show that this mechanism cannot explain our observations, because even covalently linked trimeric AcrB was stimulated by benzene (Fig. 5). (However, at present we cannot rule out the possibility that the assembly of the AcrB-AcrA-TolC tripartite complex might be affected.) In the next step, we considered the interaction between the substrates within a single AcrB protomer, by examining the binding of substrates to the distal binding pocket of AcrB, which plays a critical role in the export process29, 30. Computational docking suggested that the initial binding of benzene to the “lower” part of this pocket weakens the subsequent binding of nitrocefin, mainly to the “upper” part of the pocket, a conclusion supported by the MD simulation, showing 5 to 6 kcal/mol decrease in the absolute value of the binding energy of nitrocefin when benzene was simultaneously present in the pocket (Table 2). Since nitrocefin appears to bind to the pocket of AcrB exceptionally tightly, as judged by its very low transport KM value7 and its large calculated binding energy (see Table 2 of our previous paper9), it seemed possible, a priori, that a weakened binding of this substrate may explain its increased efflux by the minimization of the energy trough of binding. However, there are several lines of evidence against this hypothesis. First, the efflux of cefamandole, which appears to bind to the pocket much more loosely than nitrocefin on the basis of its higher transport KM (actually K0.5)7 and the smaller binding energy than nitrocefin (see Results), is nevertheless stimulated by the presence of benzene (Fig. 4). Second, in the strain expressing the V139F mutant AcrB, benzene causes hardly a decrease in the binding energy of nitrocefin (Table 2), although benzene strongly stimulates nitrocefin efflux (Fig. 7). Third, it is difficult to explain, by this hypothesis, the strong stimulation of nitrocefin efflux caused by Arg β-naphthylamide, because both substrates are expected to bind to a similar area of the pocket.
In fact, MD simulations gave us some hints that may at least partially explain the efflux stimulation data. When nitrocefin was present together with benzene in the binding site, the former was eventually pushed for about 7 Å toward the exit gate (Fig. 10B), suggesting that the presence of benzene could favor the accelerated efflux of nitrocefin. In addition, more than one molecule of small substrates, such as benzene, may bind to the same binding pocket at the same time, and this could produce stimulation of efflux.
An important factor we have not considered may be the binding of substrates in successive binding pockets in the same AcrB protomer, or in different protomers within the trimeric assembly. Thus the existence of a more proximal binding pockets, earlier identified in the symmetric AcrB crystals31–34 and by Cys mutagenesis studies30, was now confirmed to be present in the Access protomer by crystallography involving asymmetric crystals35, 36. The extrusion of a drug molecule bound in the Binding protomer thus would either require, or be at least stimulated by, the binding of the next drug molecule to the proximal binding site of the neighboring Access protomer. It seems likely that the “stimulating” substrate, such as solvents or Arg β-naphthylamide, could affect the efflux of the measured substrate, such as nitrocefin or cefamandole bound in the Binding protomer, in this manner. The stimulation by Arg β-naphthylamide, a large compound that is predicted to bind to the same area in the distal binding pocket as nitrocefin, seems to require such a mechanism. Such interaction between the neighboring protomers was indeed the mechanism proposed to explain the positive cooperativity in the efflux of various cephalosporins7 and penicillins37. If this is the case, the efflux of cefamandole is limited by the rate at which the neighboring Access protomer would bind the next cefamandole molecule when it is the only substrate present. Since solvent molecules are predicted to enter (and exit) the AcrB binding pockets rapidly, as discussed below, the cefamandole efflux is likely accelerated by the rapid entry of solvents (and other substrates that are pumped out rapidly) into the neighboring Access protomer, when these substrates are also present. Cefamandole and solvent molecules could also bind to the same protomer, and could be extruded simultaneously. We indeed found that benzene decreased the Hill coefficient for the efflux of cefamandole, an observation that supports our hypothesis.
It is well-known that AcrB pumps out solvents5. Importantly this efflux seems to occur with very high turnover numbers. Although the kinetic constants of benzene efflux through AcrB are not known, we can make a rough estimate as follows. The permeability coefficient of benzene in a conventional phospholipid bilayer was estimated as 9.9 cm/s by MD simulations38. Assuming that outer membrane bilayer has permeability about three orders of magnitude lower than the conventional bilayer39, we can estimate the permeability coefficient of benzene here as 0.01 cm/s. Thus if AcrB decreases the periplasmic benzene concentration by 10% when the cells are exposed to 100 µM benzene, creating a 10 µM concentration gradient across the outer membrane, benzene will diffuse into the periplasm at a rate of 13.2 nmol/mg cells/s. To counteract this influx, AcrB must pump out the solvent at about this rate. This can be compared with the low Vmax values for the efflux of nitrocefin and cefamandole (0.02 and 0.4 nmol/mg cells/s, respectively)7. Similarly, although the efflux rate of chloramphenicol is not known, we can assume that it is rapid, as it must penetrate across the outer membrane, mainly through the porin channels, rapidly as it is relatively small and uncharged40. These considerations suggest that the stimulators of cephalosporin efflux in AcrB are likely to be compounds that are very rapidly pumped out as substrates.
In general, it is difficult to know the rate-limiting steps in a secondary transporter. However, in one case that has been studied extensively, LacY of E. coli, it appears to be the rate of conformational alteration generating the outward-open conformer, rather than the rate of substrate binding41. Perhaps in AcrB also, it seems possible that various substrates facilitate, to a different degree, the large conformational change from the Binding to Extrusion conformation11, 28, 29 necessary for the drug export. Finally it is also possible that stimulator substrates enter rapidly into the deep binding pocket without being trapped in the proximal binding pocket42, thereby producing an accelerated functional cycle through which the efflux of other larger substrates becomes accelerated.
Supplementary Material
Acknowledgment
A. V. V. thanks Paolo Ruggerone for useful discussions and continuous support. The authors acknowledge gratefully computational resources from the Lawrence Berkeley National Laboratory (Berkeley, CA) and from CINECA (Bologna, Italy; PRACE 4th Call grant "Understanding the bacterial efflux systems: insights into structure-function relationship from all-atom simulations" and ISCRA-A Grant HP10ARSZ26).
Funding Sources
This study was supported in part by a grant from U.S. Public Health Service AI-009644 (to H. N.).
Abbreviations
- PCR
polymerase chain reaction
- MD
molecular dynamics
Footnotes
Supporting Information Available. Details of Experimental Procedures and additional Figures are presented. This material is available free of charge via the Internet at http://pubs.acs.org.
REFERENCES
- 1.Saier MH, Jr, Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. FASEB J. 1998;12:265–274. doi: 10.1096/fasebj.12.3.265. [DOI] [PubMed] [Google Scholar]
- 2.Nikaido H. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 1996;178:5853–5859. doi: 10.1128/jb.178.20.5853-5859.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ma D, Alberti M, Lynch C, Nikaido H, Hearst JE. The local repressor AcrR plays a modulating role in the regulation of acrAB genes of Escherichia coli by global stress signals. Mol. Microbiol. 1996;19:101–112. doi: 10.1046/j.1365-2958.1996.357881.x. [DOI] [PubMed] [Google Scholar]
- 4.Tsukagoshi N, Aono R. Entry into and release of solvents by Escherichia coli in an organic-aqueous two-liquid-phase system and substrate specificity of the AcrAB-TolC solvent-extruding pump. J. Bacteriol. 2000;182:4803–4810. doi: 10.1128/jb.182.17.4803-4810.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.White DG, Goldman JD, Demple B, Levy SB. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS or robA in Escherichia coli. J. Bacteriol. 1997;179:6122–6126. doi: 10.1128/jb.179.19.6122-6126.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Takatsuka Y, Chen C, Nikaido H. Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 2010;107:6559–6565. doi: 10.1073/pnas.1001460107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Nagano K, Nikaido H. Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 2009;106:5854–5858. doi: 10.1073/pnas.0901695106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Link AJ, Phillips D, Church GM. Methods for generating precise deletions and insertions in the genome of wild-type Escherichia coli: application to open reading frame characterization. J. Bacteriol. 1997;179:6228–6237. doi: 10.1128/jb.179.20.6228-6237.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Vargiu AV, Nikaido H. Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations. Proc. Natl. Acad. Sci. U. S. A. 2012;109:20637–20642. doi: 10.1073/pnas.1218348109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–461. doi: 10.1002/jcc.21334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sennhauser G, Amstutz P, Briand C, Storchenegger O, Grutter MG. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol. 2007;5:e7. doi: 10.1371/journal.pbio.0050007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J. Mol. Graph. Model. 1996;14:33–38. doi: 10.1016/0263-7855(96)00018-5. [DOI] [PubMed] [Google Scholar]
- 13.Vargiu AV, Collu F, Schulz R, Pos KM, Zacharias M, Kleinekathofer U, Ruggerone P. Effect of the F610A mutation on substrate extrusion in the AcrB transporter: explanation and rationale by molecular dynamics simulations. J. Am. Chem. Soc. 2011;133:10704–10707. doi: 10.1021/ja202666x. [DOI] [PubMed] [Google Scholar]
- 14.Elkins CA, Nikaido H. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops. J. Bacteriol. 2002;184:6490–6498. doi: 10.1128/JB.184.23.6490-6498.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 2001;45:105–116. doi: 10.1128/AAC.45.1.105-116.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Lamers RP, Cavallari JF, Burrows LL. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One. 2013;8:e60666. doi: 10.1371/journal.pone.0060666. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Matsumoto Y, Hayama K, Sakakihara S, Nishino K, Noji H, Iino R, Yamaguchi A. Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels. PLoS One. 2011;6:e18547. doi: 10.1371/journal.pone.0018547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Biochem. Pharmacol. 2006;71:910–918. doi: 10.1016/j.bcp.2005.12.008. [DOI] [PubMed] [Google Scholar]
- 19.Takatsuka Y, Nikaido H. Covalently linked trimer of the AcrB multidrug efflux pump provides support for the functional rotating mechanism. J. Bacteriol. 2009;191:1729–1737. doi: 10.1128/JB.01441-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Barducci A, Bussi G, Parrinello M. Well-tempered metadynamics: A smoothly converging and tunable free-energy method. Phys. Rev. Lett. 2008;100:020603. doi: 10.1103/PhysRevLett.100.020603. [DOI] [PubMed] [Google Scholar]
- 21.Biarnes X, Bongarzone S, Vargiu AV, Carloni P, Ruggerone P. Molecular motions in drug design: the coming age of the metadynamics method. J. Comput. Aided Mol. Des. 2011;25:395–402. doi: 10.1007/s10822-011-9415-3. [DOI] [PubMed] [Google Scholar]
- 22.Laio A, Parrinello M. Escaping free-energy minima. Proc. Natl. Acad. Sci. U. S. A. 2002;99:12562–12566. doi: 10.1073/pnas.202427399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Vargiu AV, Ruggerone P, Magistrato A, Carloni P. Dissociation of minor groove binders from DNA: insights from metadynamics simulations. Nucleic Acids Res. 2008;36:5910–5921. doi: 10.1093/nar/gkn561. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 1997;250:130–137. doi: 10.1111/j.1432-1033.1997.00130.x. [DOI] [PubMed] [Google Scholar]
- 24.Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 1999;259:841–850. doi: 10.1046/j.1432-1327.1999.00098.x. [DOI] [PubMed] [Google Scholar]
- 26.Lugo MR, Sharom FJ. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry. 2005;44:643–655. doi: 10.1021/bi0485326. [DOI] [PubMed] [Google Scholar]
- 27.Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 2000;58:624–632. doi: 10.1124/mol.58.3.624. [DOI] [PubMed] [Google Scholar]
- 28.Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature. 2006;443:173–179. doi: 10.1038/nature05076. [DOI] [PubMed] [Google Scholar]
- 29.Seeger MA, Schiefner A, Eicher T, Verrey F, Diederichs K, Pos KM. Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science. 2006;313:1295–1298. doi: 10.1126/science.1131542. [DOI] [PubMed] [Google Scholar]
- 30.Husain F, Nikaido H. Substrate path in the AcrB multidrug efflux pump of Escherichia coli. Mol. Microbiol. 2010;78:320–330. doi: 10.1111/j.1365-2958.2010.07330.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Yu EW, Aires JR, McDermott G, Nikaido H. A periplasmic drug-binding site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. J. Bacteriol. 2005;187:6804–6815. doi: 10.1128/JB.187.19.6804-6815.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Drew D, Klepsch MM, Newstead S, Flaig R, De Gier JW, Iwata S, Beis K. The structure of the efflux pump AcrB in complex with bile acid. Mol. Membr. Biol. 2008;25:677–682. doi: 10.1080/09687680802552257. [DOI] [PubMed] [Google Scholar]
- 33.Hung LW, Kim HB, Murakami S, Gupta G, Kim CY, Terwilliger TC. Crystal structure of AcrB complexed with linezolid at 3.5 A resolution. Journal of structural and functional genomics. 2013;14:71–75. doi: 10.1007/s10969-013-9154-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Tornroth-Horsefield S, Gourdon P, Horsefield R, Brive L, Yamamoto N, Mori H, Snijder A, Neutze R. Crystal structure of AcrB in complex with a single transmembrane subunit reveals another twist. Structure. 2007;15:1663–1673. doi: 10.1016/j.str.2007.09.023. [DOI] [PubMed] [Google Scholar]
- 35.Eicher T, Cha HJ, Seeger MA, Brandstatter L, El-Delik J, Bohnert JA, Kern WV, Verrey F, Grutter MG, Diederichs K, Pos KM. Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop. Proc. Natl. Acad. Sci. U. S. A. 2012;109:5687–5692. doi: 10.1073/pnas.1114944109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature. 2011;480:565–569. doi: 10.1038/nature10641. [DOI] [PubMed] [Google Scholar]
- 37.Lim SP, Nikaido H. Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. Antimicrob. Agents Chemother. 2010;54:1800–1806. doi: 10.1128/AAC.01714-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Bemporad D, Luttmann C, Essex JW. Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations. Biochim. Biophys. Acta. 2005;1718:1–21. doi: 10.1016/j.bbamem.2005.07.009. [DOI] [PubMed] [Google Scholar]
- 39.Plésiat P, Nikaido H. Outer membranes of gram-negative bacteria are permeable to steroid probes. Mol. Microbiol. 1992;6:1323–1333. doi: 10.1111/j.1365-2958.1992.tb00853.x. [DOI] [PubMed] [Google Scholar]
- 40.Nikaido H, Rosenberg EY. Porin channels in Escherichia coli: studies with liposomes reconstituted from purified proteins. J. Bacteriol. 1983;153:241–252. doi: 10.1128/jb.153.1.241-252.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Smirnova I, Kasho V, Kaback HR. Lactose permease and the alternating access mechanism. Biochemistry. 2011;50:9684–9693. doi: 10.1021/bi2014294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Ruggerone P, Murakami S, Pos KM, Vargiu AV. RND efflux pumps: structural information translated into function and inhibition mechanisms. Curr. Top. Med. Chem. 2013 doi: 10.2174/15680266113136660220. in press. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.